Adage Capital Management

Also known as: Adage Capital, Adage Capital Partners LP

Data updated June 29, 2026

Boston, Massachusetts, United States

Adage Capital Management is a Boston-based institutional investment manager with deep roots in public equity investing and selective private-company participation. It is not publicly positioned as a psychedelics specialist.

Its relevance to psychedelic medicine comes from confirmed exposure to Beckley Psytech and the 2025 atai/Beckley transaction financing. The record is strongest when framed as broad institutional healthcare capital entering the space opportunistically.

Investor Context

Institutional Investors

Investment Context

This stakeholder is listed as an Institutional Investor within Institutional Investors. Its public geography context is global. Public stage signals include Growth / Late Stage, Public Markets, and Multi-Stage. Public focus areas include Drug Development.

Public Portfolio Examples

Beckley PsytechSeries B - $80 million - Aug 16, 2021
AtaiBeckleyConcurrent private placement - $30.0M - Jun 2, 2025

Adage has source-backed exposure to both Beckley Psytech and the atai/Beckley private placement context. The investment evidence is useful for portfolio mapping, but public copy should avoid overstating Adage as a thesis-driven psychedelic platform.

Investor Type

Institutional Investor

Geographic Scope

Global

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement

Active

Investment Stage Focus

Growth / Late StagePublic MarketsMulti-Stage

Investment Focus Areas

Drug Development